LEADER 09359nam 2200601Ia 450 001 9910809636003321 005 20200520144314.0 010 $a1-61122-715-1 035 $a(CKB)2550000001041634 035 $a(EBL)3018758 035 $a(SSID)ssj0000854077 035 $a(PQKBManifestationID)12326534 035 $a(PQKBTitleCode)TC0000854077 035 $a(PQKBWorkID)10866971 035 $a(PQKB)11320841 035 $a(MiAaPQ)EBC3018758 035 $a(Au-PeEL)EBL3018758 035 $a(CaPaEBR)ebr10661696 035 $a(OCoLC)836864168 035 $a(EXLCZ)992550000001041634 100 $a20100830d2011 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aClinical aspects of psychopharmacology in childhood and adolescence /$fDonald E. Greydanus ... [et al.], editors 205 $a1st ed. 210 $aHauppauge, NY $cNova Science$dc2011 215 $a1 online resource (280 p.) 225 1 $aHealth and human development book series 300 $aDescription based upon print version of record. 311 $a1-61122-135-8 320 $aIncludes bibliographical references and index. 327 $aIntro -- CLINICAL ASPECTS OF PSYCHOPHARMACOLOGY IN CHILDHOOD AND ADOLESCENCE -- CLINICAL ASPECTS OF PSYCHOPHARMACOLOGY IN CHILDHOOD AND ADOLESCENCE -- Contents -- Foreword -- Introduction: pediatric psychopharmacology -- Modern psychopharmacology -- Conclusions -- References -- Section One: ADHD -- Chapter I Attention deficit hyperactivity disorder: pharmacologic management in children and adolescents -- Introduction -- Assessment and treatment principles -- Diagnostic criteria -- Diagnostic work up -- Comorbidity -- Discussing medications and monitoring with patients and caretakers -- Treatment planning and multimodal options -- Psychopharmacology of ADHD -- FDA approved stimulants -- Methylphenidate (MPH) preparations -- Oral short acting MPH formulations (3 - 5 hours duration) -- Multimodal treatment study of children with ADHD (MTA) study -- Preschool ADHD treatment study (pats) -- Other MPH IR formulations -- Oral intermediate acting MPH formulations (up to 8 hours duration) -- Long acting MPH formulations (up to 12 hours duration) -- MPH transdermal formulation (MTS) -- Amphetamine (AMP) preparations -- Short acting AMP formulations (up to 6 hours) -- Long acting AMP formulations (up to 8-10hHrs) -- Prodrug formulation -- Special safety considerations regarding stimulants -- Cardiovascular -- Growth -- Abuse potential -- Tics -- FDA approved non stimulants -- Atomoxetine (strattera) -- Guanfacine XRr (intuniv) -- Non FDA approved treatments -- Monitoring tools -- ADHD pharmacotherapy FaQs -- Conclusions -- Acknowledgments -- References -- Chapter II Attention deficit hyperactivity disorder and comorbid substance abuse -- Introduction -- Epidemiology -- Patterns of prescription stimulant medications -- Can childhood ADHD contribute to adolescent substance abuse? -- Detecting comorbid ADHD and SUD -- Clinical considerations. 327 $aMinimizing risks -- Impact of treatment on course of sud -- ADHD medications with low abuse potential -- Behavioral treatments -- Clinical management -- Conclusions -- References -- Section Two: Mental Health Aspects -- Chapter III Psychotherapy in the age of pharmacology -- Introduction -- A literature review -- Pharmacotherapy -- Psychotherapy -- Conclusions -- References -- Chapter IV Child and adolescent depression -- Introduction -- Epidemiology -- Clinical features -- Comorbid conditions -- Treatment -- Conclusions -- References -- Chapter V Pediatric bipolar disorder -- Introduction -- Epidemiology -- Clinical features -- Comorbid conditions -- Treatment -- Medication management -- Acute-phase treatment -- Maintenance treatment -- Treatment of comorbid disorders -- Conclusion -- References -- Chapter VI Anxiety disorders in children and adolescents -- Introduction -- Epidemiology -- Clinical features -- Treatment -- Selective serotonin re-uptake inhibitorsc (SSRIs) -- SSRI adverse effects -- Serotonin and nor-epinephrine re-uptake inhibitors -- Benzodiazepines -- Tricyclic antidepressants -- Buspirone -- Beta-blockers -- Hydroxyzine -- Mirtazepine and nefazodone -- Conclusions -- Acknowledgments -- References -- Chapter VII Oppositional defiant and conduct disorders -- Introduction -- Epidemiology -- Clinical features -- Comorbid conditions -- Treatment -- Non-medication treatments -- Medication treatments -- Psychostimulants -- Atomoxetine -- Lithium -- Atypical antipsychotics (AAs) -- Non-lithium mood stabilizers -- Other medications -- Conclusions -- References -- Chapter VIII Aggressive and violent behavior -- Introduction -- Epidemiology -- Clinical features -- Comorbid conditions -- Rule-out medical disorders -- Rule-out substance use disorders (SUDs) -- Identify psychiatric disorders -- Disruptive behavior disorders (DBDs). 327 $aMood disorders -- Anxiety disorders -- Psychotic disorders -- Impulse control disorders -- Tic disorders -- Personality disorders -- Treatment -- Conclusions -- References -- Chapter IX Tic disorders in children and adolescents -- Introduction -- Definitions -- Epidemiology -- Differential diagnosis/comorbidity -- Psychopharmacology of tic disorders -- Alpha agonists -- Antipsychotics -- Dopamine receptor agonists -- Baclofen -- Stimulants -- Antidepressants -- Anticonvulsants -- Others -- Conclusions -- Acknowledgments -- References -- Section Three: Specific Disorders -- Chapter X Autistic spectrum disorders -- Introduction -- Epidemiology -- Clinical features -- Etiology -- Assessment -- Treatment -- Conclusions -- References -- Chapter XI Schizophrenia in children and adolescents -- Introduction -- Epidemiology -- Clinical features -- Important considerations while diagnosing childhood schizophrenia -- Assessment -- Rating and diagnostic scales -- Comorbid conditions -- Treatment -- Psychopharmacology -- Atypical antipsychotics -- Clozapine -- Typical Antipsychotics -- Depot injections of medication -- Psychosocial interventions -- Conclusion -- References -- Chapter XII Cognitive-adaptive disabilities -- Introduction -- Epidemiology -- Clinical features -- Comorbid conditions -- Mood disorders -- Anxiety disorders -- Attention-deficit/hyperactivity disorder (ADHD) -- Psychotic disorders -- Other disorders -- Treatment -- Mood disorders -- Bipolar disorder -- Anxiety disorders -- Attention-deficit/hyperactivity disorder -- Psychotic disorders -- Conclusions -- References -- Section Four: Other Use -- Chapter XIII Substance abuse disorders in adolescents: pharmacologic management -- Introduction -- Alcohol -- Drug interactions -- Amphetamines -- Cocaine -- Opioids -- Heroin dependence management -- Conclusions -- Acknowledgments -- References. 327 $aChapter XIV Smoking cessation and pharmacological agents -- Introduction -- Nicotine replacement therapy -- Nicotine inhaler -- Nicotine gum -- Nicotine lozenge -- Nicotine nasal spray -- Nicotine patch -- Bupropion SR -- Varenicline -- Second-line medications -- Clonidine -- Nortriptyline -- Conclusions -- References -- Chapter XV Sleep disorders in children and adolescents -- Introduction -- Epidemiology -- Evaluation -- Insomnia -- Excessive daytime sleepiness -- Narcolepsy -- Klein-levin syndrome -- Parasomnias -- Restless legs syndrome (RLS) -- Sleep disordered breathing -- Conclusion -- Acknowledgments -- References -- Section Five: Conclusions -- Chapter XVI Pediatric psychopharmacology: where do we go from here? -- Introduction -- Pediatric psychopharmacology: quo vadis? -- Benefit of psychopharmacologic versus psychological therapies -- Benefit of psychopharmacology in pediatric mental illness -- Hope versushHype of pharmaceutical companies' for-profit research -- Intervention of governments in research -- Impact of genetics on psychopharmacology -- Results of sleep research on pediatric mental health -- Training of primary care clinicians in mental health -- Conclusions -- References -- Section Six: Acknowledgments -- Chapter XVII About the editors -- Chapter XVIII About the Department of Pediatrics and Human Development, Michigan State University College of Human Medicine, MSU/Kalamazoo Center for Medical Studies, Kalamazoo, Michigan, United States -- Mission and service -- Research activities -- Chapter XIX About the National Institute of Child Health and Human Development in Israel -- Mission -- Service and academic activities -- Research activities -- National collaboration -- International collaboration -- Targets -- Chapter XX About the book series "Health and human development". 327 $aClinical aspects of psychopharmacology in childhood and adolescence -- Index -- Blank Page. 410 0$aHealth and human development series. 606 $aPediatric psychopharmacology 606 $aAdolescent psychopharmacology 615 0$aPediatric psychopharmacology. 615 0$aAdolescent psychopharmacology. 676 $a615/.780835 701 $aGreydanus$b Donald E$01126154 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910809636003321 996 $aClinical aspects of psychopharmacology in childhood and adolescence$94089680 997 $aUNINA